Publication: Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications
| dc.contributor.author | Peter W. Andrews | en_US |
| dc.contributor.author | Uri Ben-David | en_US |
| dc.contributor.author | Nissim Benvenisty | en_US |
| dc.contributor.author | Peter Coffey | en_US |
| dc.contributor.author | Kevin Eggan | en_US |
| dc.contributor.author | Barbara B. Knowles | en_US |
| dc.contributor.author | Andras Nagy | en_US |
| dc.contributor.author | Martin Pera | en_US |
| dc.contributor.author | Benjamin Reubinoff | en_US |
| dc.contributor.author | Peter J. Rugg-Gunn | en_US |
| dc.contributor.author | Glyn N. Stacey | en_US |
| dc.contributor.other | University of Sheffield | en_US |
| dc.contributor.other | Broad Institute | en_US |
| dc.contributor.other | Hebrew University of Jerusalem | en_US |
| dc.contributor.other | UCL Institute of Ophthalmology | en_US |
| dc.contributor.other | University of California, Santa Barbara | en_US |
| dc.contributor.other | Harvard University | en_US |
| dc.contributor.other | Harvard Stem Cell Institute | en_US |
| dc.contributor.other | Jackson Laboratory | en_US |
| dc.contributor.other | Mahidol University | en_US |
| dc.contributor.other | Mount Sinai Hospital of University of Toronto | en_US |
| dc.contributor.other | Monash University | en_US |
| dc.contributor.other | University of Melbourne | en_US |
| dc.contributor.other | The Florey Institute of Neuroscience and Mental Health | en_US |
| dc.contributor.other | Walter and Eliza Hall Institute of Medical Research | en_US |
| dc.contributor.other | Hadassah University Medical Centre | en_US |
| dc.contributor.other | The Babraham Institute | en_US |
| dc.contributor.other | Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute | en_US |
| dc.contributor.other | Medicines and Health Care products Regulatory Agency | en_US |
| dc.date.accessioned | 2018-12-21T06:46:07Z | |
| dc.date.accessioned | 2019-03-14T08:02:51Z | |
| dc.date.available | 2018-12-21T06:46:07Z | |
| dc.date.available | 2019-03-14T08:02:51Z | |
| dc.date.issued | 2017-07-11 | en_US |
| dc.description.abstract | © 2017 Pluripotent stem cells may acquire genetic and epigenetic variants during culture following their derivation. At a conference organized by the International Stem Cell Initiative, and held at The Jackson Laboratory, Bar Harbor, Maine, October 2016, participants discussed how the appearance of such variants can be monitored and minimized and, crucially, how their significance for the safety of therapeutic applications of these cells can be assessed. A strong recommendation from the meeting was that an international advisory group should be set up to review the genetic and epigenetic changes observed in human pluripotent stem cell lines and establish a framework for evaluating the risks that they may pose for clinical use. | en_US |
| dc.identifier.citation | Stem Cell Reports. Vol.9, No.1 (2017), 1-4 | en_US |
| dc.identifier.doi | 10.1016/j.stemcr.2017.05.029 | en_US |
| dc.identifier.issn | 22136711 | en_US |
| dc.identifier.other | 2-s2.0-85021993873 | en_US |
| dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/123456789/41846 | |
| dc.rights | Mahidol University | en_US |
| dc.rights.holder | SCOPUS | en_US |
| dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85021993873&origin=inward | en_US |
| dc.subject | Biochemistry, Genetics and Molecular Biology | en_US |
| dc.title | Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications | en_US |
| dc.type | Conference Paper | en_US |
| dspace.entity.type | Publication | |
| mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85021993873&origin=inward | en_US |
